QUOTE AND NEWS
StreetInsider.com  Sep 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/ARIAD+Pharma+%28ARIA%29+Director+Whelan+Resigns%3B+Will+CEO+Berger+be+Next%3F/9847190.html for the full story.
Motley Fool  Sep 8  Comment 
Ariad's stock continues its double-digit percentage descent in 2014 following a rough 2013 campaign. Find out why shares continue to push lower and where Ariad's stock may head next.
TheStreet.com  Sep 5  Comment 
BOSTON (TheStreet) -- An email from Roman W. about Achillion Pharmaceuticals kicks off this week's Biotech Stock Mailbag. Roman asks, "Adam, in your latest articles discussing the important biotech events for the rest of the year, I noticed...
StreetInsider.com  Sep 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/ARIAD+Pharma+%28ARIA%29+Denies+Sarissa+Capital+NOL+Pill+Waiver/9798175.html for the full story.
StreetInsider.com  Aug 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Updates+on+Amended+13D+from+Sarissa+Capital%3B+Certain+Members+Bought+%248.8M+of+Conv.+Notes/9788358.html for the full story.
StreetInsider.com  Aug 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Grants+Exemptions+to+Advisors+Under+Rights+Agreement/9788272.html for the full story.
TheStreet.com  Aug 26  Comment 
NEW YORK (TheStreet) --aAriad Pharmaceuticalsa rose Tuesday as Roche's $8.3 billion acquisition ofaInterMunea has led the biotech sector higher. Roche will pay $74 a share for InterMune, which represents a 38% premium to Friday's closing price...
StreetInsider.com  Aug 26  Comment 
The following is a list of notable articles to help get you through the lunch hour: Standard Chartered Said to Explore Potential Rescue Financing for RadioShack (RSH) -> Read this! ARIAD Pharma (ARIA) Gains on Strong Volume Amid Promising...
SeekingAlpha  Aug 6  Comment 
Ariad Pharmaceuticals (NASDAQ:ARIA) Q2 2014 Earnings Call August 06, 2014 8:30 am ET Executives Maria E. Cantor - Senior Vice President of Corporate Affairs and Human Resources Harvey J. Berger - Principal Founder, Chairman, Chief...
TheStreet.com  Aug 6  Comment 
NEW YORK (TheStreet) -- Ariad Pharmaceuticals shares are declining -4.8% to $5.34 on Wednesday after reporting a second quarter net loss of 30 cents per share, 1 cent worse than analysts were expecting, on revenue of $12.1 million that was down...




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki